Scibase: Strong start to the year

Redeye changes our short-term estimates slightly because of a better outcome than expected in the first quarter. The sales development was strong and a healthy gross margin was reported. The costs were in line apart from higher R&D costs. We reiterate our Base case at SEK 12 per share and unchanged fair value range of SEK 5 – 20 per share.

MH

Mats Hyttinge

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.